10 September 2009
The first stage of the study made use of almost 4,000 Alzheimer’s disease patients and 8,000 healthy controls of American, British and European ancestry, with genotyping data for 530,000 SNPs. Thirteen SNPs at the APOE locus were found to be statistically significant at a genome-wide threshold of P ≤ 9.4 x 10-8. Two other SNPs reached this significance level representing newly identified associations. The first SNP (rs11136000) is located within an intron of the CLU gene (which encodes a major brain apolipoprotein, clusterin) on chromosome 8. The second SNP (rs3851179) is located 88.5kb from the PICALM gene (which encodes the phosphatidylinositol-binding clathrin assembly protein) on chromosome 11. In the second stage of this study, these two SNPs were genotyped in an independent sample of 2,000 Alzheimer’s disease patients and 2,300 age-matched and cognitively screened controls of European ancestry, and shown to be independently associated in this sample. A meta-analysis combining data from both stages also showed significant association for both SNPs (rs11136000 P = 8.5 x 10-10, OR = 0.861, 95% CI 0.82-0.90; rs3851179 P = 1.3 x 10-9, OR = 0.859, 95% CI 0.82-0.90).
The investigators then moved their focus to trying to identify functional variants responsible for these associations. A synonymous SNP (rs7982) located in exon 5 of the CLU gene was identified as being in strong linkage disequilibrium with rs11136000 and also showed similar levels of evidence for association with the combined stage1 and stage 2 study data. This SNP is located in a region coding for the beta chain of the clusterin protein and may influence a predicted exon splicing enhancer. Several potentially functional SNPs were identified at the PICALM locus, and two of these show evidence of association with putative transcription factor binding and exon splicing functions; all these functions could influence gene expression.
Comment: Well-conducted and showing robust evidence for association, the study by Harold et al. identifies new genetic variants in two gene loci of interest, providing further avenues of investigation in uncovering the genetic architecture of Alzheimer’s disease. The study by Lambert et al. [Lambert et al. (2009) Nat Genet 6 September doi:10.1038/ng439], also published in the same issue of Nature Genetics, also provides replicated evidence for the CLU gene in 5,000 Alzheimer’s disease patients and 8,000 controls of European ancestry. These two studies provide interesting epidemiological evidence for Alzheimer’s disease genetics, although much more work is required before any possible clinical benefits could be realised.